Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review.
Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances. Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.
Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy.
Alessandra
A
Bearz
Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy.
Massimiliano
M
Berretta
Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy.
Umberto
U
Tirelli
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000191:economics* / Q000556:secondary; D003362:Cost-Benefit Analysis; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000191:economics*; D011379:Prognosis; D016896:Treatment Outcome
NSCLC; chemotherapy; cost; metastases; prognoses; target agents; therapy.